The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Local Level Educational Grants Program to Increase Awareness & Understanding of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
Projects that will be considered for Pfizer support will focus on improving the care of patients by:
• Closing knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and emerging treatment paradigms.
• Addressing barriers to diagnosis and strategies that reduce burdens for patients and providers along the pathway to diagnosis
• Exploring strategies that empower patients to play an active role in understanding TTR amyloidosis and available diagnostic and treatment options
• Increasing awareness of the changing epidemiology of TTR amyloidosis with a focus on the prevalence of hereditary ATTR and wild-type ATTR subtypes in the modern era
• Increasing awareness of at risk and undiagnosed populations with TTR amyloidosis with a focus on improving strategies that facilitate the diagnosis of patients early in the disease course before overt cardiomyopathy has ensued
• Increasing awareness of bone radiotracer scintigraphy as a noninvasive alternative to invasive endomyocardial biopsy for the diagnosis of TTR cardiac amyloidosis in select patients
• Supporting the dissemination of information related to the study of emerging treatment options to improve patient important outcomes in TTR amyloidosis
This RFP will remain open while funds last. Once the full budget is spent the RFP will be closed and new requests will no longer be accepted.
Applications will be accepted on a rolling basis through October.
Geographic Scope: United States
• The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); and other entities with a mission related to healthcare professional education and/or healthcare improvement. • If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project. • For projects offering continuing education credit, the requesting organization must be accredited.
• Individual projects requesting up to $10,000 will be considered for small local/community programs. • Individual projects requesting up to $20,000 will be considered for large local/community programs.